Recently, Qilu Pharmaceutical presented a Trials in Progress poster presentation on QL1706, an innovative bifunctional antibody for immunotherapy, in two Phase III non-small cell lung carcinoma clinical studies at the 2023 American Society of Clinical Oncology Annual Meeting.
